Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Metabolic, and Stress-Related Disease Development.
TarMart Solution Ecosystem & Related Targets
“Comprehensive reagent toolkit for CRHR2 drug discovery. Select your modality below:”
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen & Membrane Protein | CRHR2 ECD-Fc Fusion Protein (>95% purity, <1EU/µg, HEK293 expressed) and Promise-ORF / Lentivirus for stable cell line construction preserving native GPCR conformation. | View CRHR2 Products |
| Benchmark Ligand | Urocortin 2 (UCN2) Analog (high purity, sequence-verified, positive control for cAMP assays); also CRH for competitive binding. | View CRHR2 Products |
| Benchmark Antibody | Anti-CRHR2 Monoclonal Antibody (recombinant, for expression and pathway validation). | View CRHR2 Products |
| Validator | CRHR2 siRNA Set for knockdown verification and off-target/specificity controls. | View CRHR2 Products |
| Related Target A | CRHR1 – essential for selectivity counter-screening (avoiding stress/anxiety off-target effects). | View CRHR1 Products |
| Related Target B | CRH (native ligand) & UCN2 (endogenous high-selectivity CRHR2 agonist). | View CRH Products, View UCN2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native GPCR conformation for functional assays | Lentivirus-mediated stable cell lines preserve 7-TM topology for cAMP/calcium flux. |
| CRHR1 subfamily off-target selectivity | High-purity CRHR1 and CRHR2 cell lines and ECD-Fc proteins for parallel counter-screening. |
| Cross-species evaluation (cyno/mouse) | Human / Mouse / Cynomolgus CRHR2 proteins (>95% purity) available; theoretical MW confirmed. |
| Lack of reliable controls | Sequence-verified Urocortin 2/3 analogs and target-specific siRNA sets for accurate signal background. |
| False positives / specificity | siRNA knockdown validation included for precise background signal verification. |
Live CRHR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CRHR2 therapeutics is transitioning from traditional peptide-based endocrine approaches to next-generation long-acting peptide agonists, small-molecule modulators, and receptor-selective biologics. As a Class B1 GPCR, CRHR2 plays critical roles in cardioprotection, skeletal muscle preservation, metabolic homeostasis, and tissue fibrosis. First-in-class programs are advancing preclinical candidates toward IND-enabling studies, with functional selectivity over CRHR1 representing the primary differentiation hurdle. Next-wave innovations include extended half-life formulations and allosteric modulators that strictly avoid CRHR1 cross-reactivity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Agonists | Specialized Biotechs, Academic Consortia | Heart Failure, Cardioprotection, Muscle Atrophy | cAMP Accumulation Assay (need stable CRHR2 cells via Lentivirus) |
| Small Molecule Modulators | Early-Stage Pharma, Major R&D | Pulmonary Arterial Hypertension, IBD, Metabolic Disorders | CRHR1/CRHR2 Selectivity Panel (high-purity ortholog proteins) |
| Biologic Antagonists / mAbs | Emerging Biotech, Startups | Fibrotic Disease, Stress-Related Pathology, Rare Diseases | Binding & Internalization Assay (need CRHR2 ECD-Fc and stable cells) |